Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1381
-
1382
-
1383
-
1384
-
1385
-
1386
-
1387
-
1388
-
1389
-
1390
Spt5 protein is significantly decreased in <i>fog<sup>sk8</sup></i> embryos.
Published 2008“…Confocal images of lateral views are shown, with the anterior to the left and dorsal up. (E) Western blot of wild-type (WT) and <i>fog<sup>sk8</sup></i> embryonic extracts at 19 hpf and 24 hpf shows substantial decrease in maternal Spt5 protein in the mutant. …”
-
1391
-
1392
-
1393
-
1394
-
1395
Riociguat decreases hyperoxia-induced vascular remodeling.
Published 2018“…<p>(<b>A</b>, <b>C</b>) Double immunofluorescence staining for vWF (green signal) and α-SMA (red signal) plus DAPI nuclear stain (blue signal). …”
-
1396
Predicted targets of miR-337-3p decrease in mRNA expression on over-expression of miR-337-3p.
Published 2012“…In column 6, the number of genes that contain the listed motif, but do not contain the canonical miR-337-3p seed sequence target, is given in parentheses. (E) Proportional Venn diagram showing the relationship among the genes that decrease ≥2 fold in expression and contain one or more of the five 7-mers corresponding to the mature miR-337-3p sequences.…”
-
1397
The Transition from a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk
Published 2022“…Conclusions</p> <p>A transition from an increase to a decrease in AUC C-peptide approximately 1.5 years pre-diagnosis was validated in two independent cohorts. …”
-
1398
-
1399
GluN2A(D731N) reduces the agonist potency.
Published 2017“…(<b>C,E</b>) The composite glutamate (in the presence of 100 μM glycine) concentration-response curves reveal a significant decrease in glutamate potency in both di-heteromeric (<b>C</b>) and tri-heteromeric (<b>E</b>) GluN2A(D731N)-containing NMDARs compared to wild type receptors. …”
-
1400